Vaxcyte, Inc. (NASDAQ:PCVX) Receives $136.50 Consensus Target Price from Analysts

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have been assigned an average recommendation of “Buy” from the ten analysts that are currently covering the firm, MarketBeat reports. Nine analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $136.50.

Several equities research analysts have commented on the stock. Bank of America cut their price target on shares of Vaxcyte from $157.00 to $137.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st. Cantor Fitzgerald assumed coverage on shares of Vaxcyte in a report on Tuesday, April 22nd. They issued an “overweight” rating on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 target price on shares of Vaxcyte in a report on Tuesday, April 8th. Evercore ISI raised shares of Vaxcyte to a “strong-buy” rating in a report on Monday, March 31st. Finally, Guggenheim reaffirmed a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th.

Vaxcyte Price Performance

Shares of NASDAQ:PCVX opened at $30.90 on Friday. The company’s 50-day moving average price is $43.32 and its two-hundred day moving average price is $72.46. Vaxcyte has a one year low of $27.66 and a one year high of $121.06. The stock has a market capitalization of $3.99 billion, a PE ratio of -6.72 and a beta of 1.27.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period in the previous year, the company earned ($0.85) EPS. On average, analysts anticipate that Vaxcyte will post -4.21 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the transaction, the chief operating officer now directly owns 154,931 shares of the company’s stock, valued at approximately $11,351,794.37. This trade represents a 4.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in PCVX. Whipplewood Advisors LLC bought a new position in shares of Vaxcyte during the fourth quarter worth approximately $28,000. Smartleaf Asset Management LLC increased its stake in Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after acquiring an additional 260 shares during the last quarter. AlphaQuest LLC bought a new position in Vaxcyte in the first quarter valued at approximately $33,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Vaxcyte in the first quarter valued at approximately $35,000. Finally, National Bank of Canada FI bought a new position in Vaxcyte in the fourth quarter valued at approximately $41,000. 96.78% of the stock is owned by institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.